Colorectal cancer

EQS-News: Mainz Biomed Provides Full Year 2022 Financial Results

Retrieved on:

Saturday, April 15, 2023

Pancreatic cancer, CRC, Cancer, Expansion, Gene expression, Biomarker, Messenger, Colorectal cancer, Growth, Management, Vaccine, Qiagen

The issuer is solely responsible for the content of this announcement.

Key Points:

The issuer is solely responsible for the content of this announcement.
BERKELEY, US – MAINZ, Germany – April 10, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended December 31, 2022.
“Throughout the year we operated in a position of financial strength enabling us to achieve meaningful growth across commercial, operational and product development fronts,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed.
“Heading into fiscal 2023, we have a defined set of priorities intended to facilitate our goal of becoming the leading developer of premier cancer-focused early detection and disease prevention molecular diagnostics.”
Expanded international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC), including five new lab partners in Germany and Italy
Initiated and commenced patient enrollment in European and U.S. studies (ColoFuture/eAArly DETECT) evaluating the integration of Mainz’s portfolio of proprietary and novel gene expression (mRNA) biomarkers into ColoAlert; potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC; Results from both studies expected in 2023
Initiated ReconAAsense, U.S. Pivotal Clinical Study with Company’s CRC screening test; anticipate commencing patient enrollment in the second half of 2023
Enhanced leadership team with appointments to Board of Directors and Company executives to lead commercial and product development groups, with former executives and senior management from Roche, Abbott, Luminex, and Qiagen; expanded Medical Advisory Board of global leaders in molecular diagnostic development
Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer

EQS-News: Epigenomics AG: Chief Executive Officer Greg Hamilton Resigns

Retrieved on:

Saturday, April 15, 2023

Executive, CMS, Centers for Medicare & Medicaid Services, Epigenomics AG, Supervisory board, Medicare, RTÉ Executive Board, ECX, Colorectal cancer, OTCQX, Epigenomics, FDA, German company law, Property management, Management

Berlin (Germany), April 12, 2023 - The Chief Executive Officer of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), Greg Hamilton, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective June 30, 2023.

Key Points:

Berlin (Germany), April 12, 2023 - The Chief Executive Officer of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), Greg Hamilton, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective June 30, 2023.
Between now and the resignation date Greg Hamilton will continue to lead the Company’s restructuring efforts in coordination with the Supervisory Board.
Dr. Helge Lubenow, Chairman of the Supervisory Board of Epigenomics AG, thanked Greg Hamilton on behalf of the entire Supervisory Board: “Greg Hamilton has taken a leading role in the commercialization of Epi ProColon and the development of the "Next-Gen" colorectal cancer screening test over the last years and has driven the process with his experience and strategic vision."
Against this backdrop, the resignation of Greg Hamilton now also takes place.

EQS-News: Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany

Retrieved on:

Saturday, April 15, 2023

Diagnosis, Cancer, BGM, Physician, CRC, Education, Colorectal cancer, Pharmaceutical industry

BERKELEY, US – MAINZ, Germany – April 4, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies, have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) into their respective corporate health programs.

Key Points:

BERKELEY, US – MAINZ, Germany – April 4, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies, have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) into their respective corporate health programs.
“At Mainz Biomed, we believe that everyone should have access to colorectal cancer screening, since almost 73,000 cases of colorectal cancer are diagnosed annually in Germany,” said Guido Baechler, Chief Executive Officer of Mainz Biomed.
“Including ColoAlert in corporate health programs provides an easy way for employees to get the testing they need.
As part of its commitment to the BGM program, Mainz Biomed provides education to employees and physicians on CRC and recommendations for next steps.

Corning and Memorial Sloan Kettering Cancer Center Announce Health Equity Fellowship to Explore Disparities in Cancer Outcomes

Retrieved on:

Thursday, April 13, 2023

CORNING, N.Y., April 13, 2023 (GLOBE NEWSWIRE) -- Corning Incorporated (NYSE: GLW) and Memorial Sloan Kettering Cancer Center (MSK) announced today that Dr. Francisco Sanchez-Vega, Ph.D., has been awarded the Corning-MSK Health Equity Research Fellowship, a two-year grant that funds research into the broad disparities in cancer outcomes for patients in historically underserved communities.

Key Points:

CORNING, N.Y., April 13, 2023 (GLOBE NEWSWIRE) -- Corning Incorporated (NYSE: GLW) and Memorial Sloan Kettering Cancer Center (MSK) announced today that Dr. Francisco Sanchez-Vega, Ph.D., has been awarded the Corning-MSK Health Equity Research Fellowship, a two-year grant that funds research into the broad disparities in cancer outcomes for patients in historically underserved communities.
The fellowship provides an opportunity for Corning to extend its long-standing relationship with MSK’s world-class cancer center through MSK’s Office of Health Equity.
Dr. Sanchez-Vega will use the Corning-MSK Health Equity Research Fellowship to examine the genomic, clinical, and socioeconomic causes of disproportionally negative outcomes of colorectal cancer in Black patients in the United States.
Members of the Corning-MSK Health Equity Research Fellowship selection committee included:
Dr. Michelle Johnson, M.D., M.P.H., Vice Chair of Health Equity, Department of Medicine and Director of Clinical Cardiology, Memorial Sloan Kettering Cancer Center
Dr. Michael Tuttle, M.D., Chief of the Endocrinology Service, Memorial Sloan Kettering Cancer Center

Mainz Biomed Provides Full Year 2022 Financial Results

Retrieved on:

Monday, April 10, 2023

Pancreatic cancer, CRC, Cancer, Expansion, Gene expression, Biomarker, Messenger, Colorectal cancer, Growth, Management, Vaccine, Qiagen

BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended December 31, 2022.

Key Points:

BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended December 31, 2022.
“Throughout the year we operated in a position of financial strength enabling us to achieve meaningful growth across commercial, operational and product development fronts,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed.
“Heading into fiscal 2023, we have a defined set of priorities intended to facilitate our goal of becoming the leading developer of premier cancer-focused early detection and disease prevention molecular diagnostics.”
Expanded international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC), including five new lab partners in Germany and Italy
Initiated and commenced patient enrollment in European and U.S. studies (ColoFuture/eAArly DETECT) evaluating the integration of Mainz’s portfolio of proprietary and novel gene expression (mRNA) biomarkers into ColoAlert; potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC; Results from both studies expected in 2023
Initiated ReconAAsense, U.S. Pivotal Clinical Study with Company’s CRC screening test; anticipate commencing patient enrollment in the second half of 2023
Enhanced leadership team with appointments to Board of Directors and Company executives to lead commercial and product development groups, with former executives and senior management from Roche, Abbott, Luminex, and Qiagen; expanded Medical Advisory Board of global leaders in molecular diagnostic development
Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer

TOUR de TUSH RAISES MONEY FOR YOUNG ONSET COLORECTAL CANCER RESEARCH

Retrieved on:

Wednesday, April 5, 2023

Coalition, Research, Lehigh Valley, Patient, Colorectal cancer, NBA Nation (tour), American Cancer Society, Disease, Tourism, Birth control

Held from May 1-31, 2023, Tour de Tush is hosted by the Colon Cancer Coalition to raise awareness and support research into the rise of young onset colorectal cancer (diagnosed before the age of 50).

Key Points:

Held from May 1-31, 2023, Tour de Tush is hosted by the Colon Cancer Coalition to raise awareness and support research into the rise of young onset colorectal cancer (diagnosed before the age of 50).
The Coalition is excited to welcome back Olympus Corporation of the Americas as the presenting sponsor for the 2023 Tour de Tush.
Funds raised during this event will support research around young onset colorectal cancer as well as quality of life issues for young patients.
“Colorectal cancer is on track to become the leading cause of cancer deaths for adults under 50 by 2030,” states Chris Evans, president of the Colon Cancer Coalition.

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Retrieved on:

Tuesday, April 4, 2023

Dicarboxylic acid, Docetaxel, Bevacizumab, Therapy, FOLFIRI, Oxaliplatin, Lung cancer, Lung, NCNA, Patient, Colorectal cancer, Melanoma, Irinotecan, Safety, Cryptocurrency, Pharmaceutical industry, Medical imaging

EDINBURGH, United Kingdom, April 04, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

Key Points:

EDINBURGH, United Kingdom, April 04, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
As of December 31, 2022, NuCana had cash and cash equivalents of £41.9 million compared to £50.8 million as of September 30, 2022 and £60.3 million at December 31, 2021.
NuCana continues to advance its various clinical programs and reported a net loss of £15.2 million for the quarter ended December 31, 2022, as compared to a net loss of £13.6 million for the quarter ended December 31, 2021.
Net loss for the year ended December 31, 2022 was £32.0 million, compared to a net loss of £40.5 million for the year ended December 31, 2021.

Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany

Retrieved on:

Tuesday, April 4, 2023

Diagnosis, Cancer, BGM, CRC, Education, Physician, Colorectal cancer, Pharmaceutical industry

BERKELEY, Calif. and MAINZ, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) into their respective corporate health programs.

Key Points:

BERKELEY, Calif. and MAINZ, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) into their respective corporate health programs.
“At Mainz Biomed, we believe that everyone should have access to colorectal cancer screening, since almost 73,000 cases of colorectal cancer are diagnosed annually in Germany,” said Guido Baechler, Chief Executive Officer of Mainz Biomed.
“Including ColoAlert in corporate health programs provides an easy way for employees to get the testing they need.
As part of its commitment to the BGM program, Mainz Biomed provides education to employees and physicians on CRC and recommendations for next steps.

Vizient Examines Care Models for Arrhythmia, How to Improve Screening Rates for Colorectal Cancer in Latest Medical Device Tech Watch

Retrieved on:

Thursday, April 13, 2023

Vizient, Inc. released its latest Medical Device Tech Watch, examining care models for cardiac arrhythmia, methods for improving colorectal cancer screening rates and how optimizing surgical tray standardization can reduce costs and improve operational efficiencies.

Key Points:

Vizient, Inc. released its latest Medical Device Tech Watch, examining care models for cardiac arrhythmia, methods for improving colorectal cancer screening rates and how optimizing surgical tray standardization can reduce costs and improve operational efficiencies.
“This edition of Tech Watch explores a variety of topics, including emerging artificial intelligence technologies and efficiencies in the operating room,” said Doug Beinborn, associate principal, Vizient.
Vizient conducted a tray standardization initiative with a member-provider, identifying ways to reduce costs and improve efficiency without impacting clinicians or patient care.
Tech Watch delivers data-driven insights on trends and dynamics affecting healthcare, providing insights that drive innovation in care delivery.

Alpha Cancer Technologies (ACT) Publishes Pre-Clinical Study Results in Cancer Cell International Demonstrating Excellent Safety and Significant Anti-Tumor Activity from the Company’s Next Generation ADC, ACT-903

Retrieved on:

Thursday, April 6, 2023

Human AFP acts as a shuttle protein, transporting a variety of molecules including targeted anti-cancer agents inside the cell via the AFP receptor.

Key Points:

Human AFP acts as a shuttle protein, transporting a variety of molecules including targeted anti-cancer agents inside the cell via the AFP receptor.
Studies were performed to investigate the use of ACT-101 conjugated with maytansine for targeted toxin delivery to cancer.
A significant reduction of tumor burden compared to control was achieved in the 40 and 50 mg/kg dose groups.
The observed efficacy and excellent tolerability of ACT-903 in these xenograft models support advancing the development of ACT-903 into clinical studies.